You are on Home >> Ranbaxy gets sanctioned by the FDA to Instigate Generic Lipitor and Atorvastatin in the U.S. Market

Ranbaxy gets sanctioned by the FDA to Instigate Generic Lipitor and Atorvastatin in the U.S. Market

Since 2006 there were a few issues with Ranbaxy pharmaceuticals going on with regards to the quality manufacturing of the generic medication Lipitor.  Generic Lipitor is the generic version of the brand medication Lipitor which lost the U.S patent protection as the medication was not up to the quality standards of the FDA (Food and Drug Administration). But after a long struggle, Ranbaxy pharmaceuticals Inc (RPI) which is the wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL) got an approval to manufacture and market generic Lipitor and Atorvastatin.

What is Lipitor/ generic Lipitor meant for?

Generic Lipitor is the generic medication of the brand name Lipitor which is used to control cholesterol level in the body. Lipitor is the most popular and most demanded medication in the US market for cholesterol treatment.  Lipitor   is also the brand name of the medicine Atorvastatin calcium which is a prescribed medication used for lowering cholesterol content and triglycerides in the blood.

The endemic nature of Hyperlipidemia and high cholesterol is a common health problem that majority of the population in the western countries especially US population face. Due to high cholesterol and triglycerides in the majority of the western population experienced severe health complications such as strokes, and cardiovascular disease.  It can also be used for patients with Diabetes, protecting against vascular-related problems. Thus, this health problem made Lipitor and its generic version the most beloved and preferred medication in the western countries.

Many analysts and pharmacists all around the world have kept their eyes on Ranbaxy if they would be able to get the generic version of Lipitor in the market as the patent for the most top selling branded medication has expired.  On Wednesday 30th November 2012 FDA approved the manufacturing and marketing of generic Lipitor and Atorvastatin in the US market. Atorvastatin solely generated annual sales of $7.89 billion in the United States in September 2011.

About Ranbaxy

Ranbaxy laboratories limited is the largest pharmaceutical company in India that manufactures branded as well as generic medications for various health ailments that are low cost medication. Ranbaxy has many laboratories and research centers all over the world and has customers in over 125 countries. This pharmaceutical company is the most trusted and accepted drug manufacturing company all around the globe.